Patent intelligence · US
US 11939581
Methods and compositions for targeting PD-L1
Methods and compositions for targeting PD-L1
Patent details — US 11939581
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 26, 2024
- Expiration
- Mar 21, 2044
- Applicant
- Aligos Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/7105, A61K45/06, A61P
Quick answer
US 11939581 (Methods and compositions for targeting PD-L1) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aligos Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/7105, A61K45/06, A61P, A61P31/20, A61P35/00
More from Aligos Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384779
Bicyclic compounds
granted -
US 12252481
Anti-viral compounds
granted -
US 12180192
Modulators of THR-β and methods of use thereof
granted -
US 12129469
Modified short interfering nucleic acid (siNA) molecules and uses thereof
granted -
US 12065428
Anti-viral compounds
granted -
US 12018015
Methods and compositions for targeting PD-L1
granted -
US 11957683
Bicyclic compounds
granted -
US 11952374
Bicyclic compounds
granted
Related coverage
Frequently asked questions
What is US patent 11939581?
US 11939581 (Methods and compositions for targeting PD-L1) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11939581?
Aligos Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 11939581 expire?
Our index shows an expiration date of Mar 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.